17 January 2025 in ISME Communications
Because accessing the small intestine is technically challenging, studies of the small intestinal microbiome are predominantly conducted in patients rather than in healthy individuals. Invasive clinical procedures, such as endoscopy or surgery, usually performed for therapeutic purposes, are typically required for sample collection. Although stomas offer a less invasive means for repeated sampling, their use remains restricted to patient populations. As a result, the small intestinal microbiome of healthy individuals remains largely understudied. This study evaluated a novel ingestible medical device for collecting luminal samples from the small intestine. A monocentric interventional trial (NCT05477069) was conducted on 15 healthy subjects. Metagenomics, metabolomics, and culturomics were used to assess the effectiveness of the medical device in characterizing the healthy small intestinal microbiome and identifying potential biomarkers. The small intestinal microbiota differed significantly from the fecal microbiota, displaying high inter-individual variability, lower species richness and reduced alpha diversity. A combined untargeted and semi-targeted LC–MS/MS metabolomics approach identified a distinct small intestinal metabolic footprint, with bile acids and amino acids being the most abundant metabolite classes. Host- and host/microbe-derived bile acids were particularly abundant in small intestinal samples. Using a fast culturomics approach on two small intestinal samples, we achieved species-level characterization and identified 90 bacterial species, including five potentially novel ones. This study demonstrates the efficacy of our novel sampling device in enabling comprehensive small intestinal microbiome analysis through an integrative, multi-omics approach. This approach allows distinct microbiome signatures to be identified between small intestinal and fecal samples.
19 September 2024 in bioRxiv
The gut microbiome is a complex ecosystem varying along different gut sections, consisting of metabolites from food, host, and microbes. Microbially-derived metabolites like bile acids and short-chain fatty acids interact with host physiology. Current studies often use fecal samples, which don’t fully represent the upper gut due to stratification. To sample the proximal gut microbiome, endoscopic methods or new non-invasive devices are used. We developed an approach combining untargeted and semi-targeted metabolomics using a Q-Exactive Plus Orbitrap mass spectrometer to profile gut metabolites. We initially selected 49 key metabolites based on specific criteria, validated them through repeatability tests, and created a compound database with TraceFinder software. Our workflow enables molecule annotation in untargeted studies while validating 37 metabolites in semitargeted analyses. This method, applied to clinical trial samples ( NCT05477069 ), shows promise in discovering new gut metabolites. Highlights: Innovative Combined Metabolomics Workflow: The study introduces a combined approach that integrates semi-targeted and untargeted metabolomics analyses to characterized small intestinal and fecal metabolomes. This method allows for the relative quantification of carefully selected metabolites and the reanalysis of these metabolites using evolving curated databases, enhancing the understanding of the gut microbiome-health axis. Untargeted Metabolomics Strategy: The untargeted approach aims to determine the global metabolic profile of samples and discover new metabolites. This involves processing data through a detailed pipeline, statistical analysis, and feature annotation using tools like MZmine, MetaboAnalyst, and the GNPS platform. Proof of Concept on Clinical Samples: The combined approach was tested on clinical samples from a participant in a clinical trial, revealing distinct metabolomes between small intestinal content and fecal samples. This proof of concept demonstrated the method’s ability to identify and quantify metabolites, showing significant differences in metabolite abundance between the two sample types and highlighting the potential for discovering new bile acids through molecular networking.
1 October 2026 in SSRN Electronic Journal
Isoprenoid quinones are ubiquitous redox lipids that mediate electron transfer in various cellular processes across all domains of life. These molecules also serve as taxonomic and metabolic markers, facilitating the characterisation of microbial communities. However, their structural diversity and extreme hydrophobicity are challenging for comprehensive detection and quantification in complex biological matrices. In this study, we present a semi-quantitative HPLC-MS/MS method that enables the sensitive analysis of the widest range of quinones reported to date. Using a 16-quinone standard mixture, we optimized separation within a 14-minute HPLC gradient and achieved a sensitivity ranging from 55.2 to 0.3 femtomoles in targeted analyses. When applied to sewage sludges sampled weekly over three weeks, our method detected 57 quinones, revealing distinct quinone profiles at various wastewater treatment stages. This rapid and sensitive workflow enables quinone profiling in complex samples, and holds significant promise for advancing microbial ecology, environmental monitoring, and biotechnological applications.